Kornimate/medical-research-clean huggingface dataset:
diffusion mri for quantitative assessment of myofascial pain

Conditions: Masticatory Myofascial Pain Syndrome

Summary: the purpose of this study is to assess the diagnostic accuracy of diffusion mri for evaluation of the jaw muscles for patients with masticatory myofascial pain syndrome.


Eligibility criteria:
inclusion criteria: * men and women 18-65 years of age * ability to give informed consent * symptoms meeting criteria for normal or latent/active temporomandibular myofascial pain exclusion criteria: * contraindications to mri scanning including severe obesity or difficulty in laying in a supine position, intracranial clips, metal implants, external metallic devices/objects/clips within 10mm of the head, suspected or confirmed metal in the eyes (history of welding or similar activity), claustrophobia, cardiac pacemaker or pacing wires * pregnancy or breast feeding * dental implants with metal on the same side of the temporomandibular pain * traumatic injury of masticatory muscles or temporomandibular joint within last 12 months * mandibular fracture within last 12 months * initiation of additional treatment of myofascial pain within the past 1 month
a novel therapeutic approach to treat chronic pelvic pain

Conditions: Chronic Pelvic Pain

Summary: to collect pilot data and assess the feasibility of a trial employing a single-arm intervention to study the effects of combined self-induced therapeutic tremors plus mindfulness on symptoms of chronic pelvic pain among women diagnosed with chronic pelvic pain.

the estimated prevalence of chronic pelvic pain among women is 2-24%. the etiology of chronic pelvic pain is multifactorial making it very difficult to manage clinically. evidenced-based therapies are limited and a multidisciplinary approach, including complementary and alternative medicine, to treat women with chronic pelvic pain may be the best approach. this study assess the feasibility of conducting randomized controlled trial with a single arm intervention to treat symptoms of chronic pelvis pain among women diagnosed with chronic pelvic pain. the intervention will consist of a novel combined alternative therapy intervention among women with chronic pelvic pain (self-induced therapeutic tremor plus mindfulness). this is a clinically significant project as lifestyle interventions to treat chronic pelvic pain are urgently needed, given the prevalence and the healthcare costs associated with chronic pelvic pain. study objective: the primary purpose of this project is to collect pilot data and assess the feasibility of a single arm intervention trial to improve symptoms of cpp among women diagnosed with cpp. intervention arm - combined alternative therapy: the novel combined alternative therapy that will be studied consists of self-induced therapeutic tremors (sitt) plus mindfulness. sitt is the intentional induction of the body's innate tremor mechanism to treat hyperarousal and muscle tension, which is characteristic of cpp. sitts are thought to restore somatic and autonomic nervous system homeostasis, by discharging sympathetic arousal and down-regulating the autonomic nervous system. previous work has shown that mindfulness training may improve symptoms of cpp, however there are no studies investigating the impact that the combination of mindfulness coupled with sitts may have on the symptoms of cpp.

Eligibility criteria:
inclusion criteria: * women * age \>18 * physical requirements: be able to complete the intervention sessions * not seeking other therapeutic modalities, such as acupuncture, pt, during study duration * free from surgery for \>3 months * being treated clinically for chronic pelvic pain and related conditions * cpp of 6 months or more (to be considered chronic) * availability to commit to the 4-week intervention (two 60-minute sessions per week at a specified time, for 4 weeks) * internet access and consistent access to phone/email/text communication exclusion criteria: * pregnancy * illicit substance use (e.g. cocaine, methamphetamines, heroin, street drugs) - marijuana and cbd oil and related supplements will be considered on a case-by-case basis by the principal investigators * current psychiatric illness/social situation that would limit compliance with study requirements, as determined by the principal investigators
using online food retail "nudges" to promote healthier beverage intake among low-income children

Conditions: Obesity

Summary: the specific aims of this proposal are to 1) develop online food retail nudges to discourage sugary drink purchases and promote healthier substitutes; 2) examine the impact of online store nudges on purchases of sugary drinks in an online randomized controlled experiment with low-income parents, including supplemental nutrition assistance program (snap) and women, infants, and children (wic)-participating parents, of children age 1-5 years; and 3) disseminate findings to retailers, including those participating in the snap online purchasing pilot.


Eligibility criteria:
inclusion criteria: for aim 1, the inclusion criteria are as follows: * parent (or caregiver) of children ages 1-5 years; * the ability to read and write in english; * aged 18 years or older; * household income at or below 185% of the federal poverty level; * previously purchased fruit drinks for their children; * have ever shopped for groceries online in the last 12 months, * live in the us, and * have access to a personal computer, laptop, or tablet. the inclusion criteria for aim 2 are identical to the inclusion criteria for aim 1, except the researchers will not aim to recruit exclusively parents who have previously purchased sugary drinks for their children or who have ever shopped for groceries online in the last 12 months. exclusion criteria: the exclusion criteria for aim 1 include: * not parent (or caregiver) of children ages 1-5 years; * aged \ 99 years; * lack the ability to read and speak english; * household income above 185% the federal poverty level; * have never purchased fruit drinks for their children; * have never shopped for groceries online in the last 12 months; * do not live in the us, and; * do not have access to a personal computer, laptop, or tablet. the exclusion criteria for aim 2 are identical to the exclusion criteria for aim 1, except participants who have never purchased sugary drinks for their children and have never shopped for groceries online in the last 12 months will not be excluded.
ovarian stimulation using recombinant follicle-stimulating hormone (fsh) and gonadotrophin releasing hormone (gnrh) agonist in alternate days

Conditions: Infertility

Summary: the present prospective study was designed to compare the effects of administering a daily dose of gonadotrophin releasing hormone (gnrh) antagonist vs. an alternate-day dosage of gnrh agonist on ovarian response and in vitro fertilization (ivf) outcome in patients stimulated with recombinant follicle-stimulating hormone (fsh) and human chorionic gonadotrophin (hcg) microdose.

inclusion criteria were as follows: women of good physical and mental health, under 37 years old, with regular menstrual cycles of 25-35 days, normal basal fsh and luteinizing hormone (lh) levels, body mass index (bmi) less than 30 kg/m2, presence of both ovaries and intact uterus, absence of polycystic ovaries, endometriosis, or gynaecological / medical disorders and a negative result in a screening for sexually transmitted diseases. no patient had received any hormone therapy for at least 60 days preceding the study. eligible patients who agreed to participate were randomized in two treatment groups. patients were allocated to a gnrh analogue treatment group according to a computer-generated randomization table.

Eligibility criteria:
inclusion criteria: * women of good physical and mental health * under 37 years old, with regular menstrual cycles of 25-35 days * normal basal fsh and lh levels * bmi less than 30 kg/m2 * presence of both ovaries and intact uterus * absence of polycystic ovaries * endometriosis, or gynaecological / medical disorders and a negative result in a screening for sexually transmitted diseases * all patients signed a written informed consent form * no patient had received any hormone therapy for at least 60 days preceding the study.

Keywords: ovarian stimulation gnrh agonist gnrh antagonist hcg microdose icsi
s9031-9333-0106-0112-a study of biomarkers in samples from patients with acute myeloid leukemia treated with standard chemotherapy with or without gemtuzumab ozogamicin

Conditions: Leukemia

Summary: rationale: studying samples of bone marrow and blood from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. purpose: this research trial studies biomarkers in samples from patients with acute myeloid leukemia treated with standard chemotherapy with or without gemtuzumab ozogamicin.

objectives: * to determine whether measuring biomarkers in less-differentiated acute myeloid leukemia (aml) blasts significantly improves their predictive accuracy to predict clinical outcomes for patients receiving induction/consolidation chemotherapy with and without gemtuzumab ozogamicin. * to develop and validate novel predictive biomarker models for predicting clinical outcomes for aml patients receiving induction/consolidation chemotherapy with and without gemtuzumab ozogamicin. outline: dna and rna extracted from archived bone marrow and peripheral blood samples are analyzed for genomic mutations (cebpa, flt3, idh1/2, kit, npm1, runx1, tp53, and wt1) and transcriptional biomarkers (baalc, ccna1, cd34, cebpa, erg, evi1, flt3, il3ra, mcl1 \[two splice variants\], mn1, runx1, and wt1) by pcr and real-time pcr. data are then analyzed by the gene scan software.

Eligibility criteria:
disease characteristics: * pretreatment bone marrow (bm) and peripheral blood (pb) samples obtained from southwest oncology group ( swog) leukemia repository for adult patients enrolled on swog-9031, swog-9333, swog-s0106, and swog-s0112 * samples restricted to those patients from these studies with at least 3 or more vials of remaining material in the swog leukemia repository and vials containing at least 1.5 x 10\^7 cells/vial * samples from patients who received standard induction with cytarabine (ara)/daunorubicin hydrochloride (dnr) with the addition of gemtuzumab ozogamicin (mylotarg®) on one arm of s0106 patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: adult acute myeloid leukemia with 11q23 (mll) abnormalities adult acute myeloid leukemia with del(5q) adult acute myeloid leukemia with inv(16)(p13;q22) adult acute myeloid leukemia with t(15;17)(q22;q12) adult acute myeloid leukemia with t(16;16)(p13;q22) adult acute myeloid leukemia with t(8;21)(q22;q22) adult acute myeloid leukemia
microarray analysis of sinus samples from patients with and without chronic rhinosinusitis.

Conditions: Chronic Rhinosinusitis

Summary: the purpose of this study is to compare the bacteria, fungi, and viruses that are present in the sinuses of patients with chronic rhinosinusitis to patients without sinus disease using a new technology, called a microarray, that will allow more accurate identification of microorganisms than current laboratory methods.


Eligibility criteria:
inclusion criteria: * age 18 years or older * history of chronic rhinosinusitis (crs) * impaired crs-specific quality of life * evidence of sinus disease on a ct scan exclusion criteria: * control patients with any evidence of crs by history, survey, or imaging criteria
a real-world study of covid-19 infection in patients with malignant lymphomas participating in clinical trials

Conditions: Malignant Lymphoma; Clinical Trial; COVID-19

Summary: this study focuses on the population of malignant lymphoma patients who are also in clinical research. through a real world cross-sectional survey of infection and death risk during the covid-19 pandemic in guangzhou from december 2022 to january 2023, this study aims to clarify the risk, level and mortality of lymphoma patients infected with covid-19 during their clinical research, and provide necessary research data for chinese lymphoma patients during the covid-19 pandemic,


Eligibility criteria:
inclusion criteria: (1) the diagnosis of lymphoma was confirmed by pathology according to world health organization (who)-criteria; (2) diagnosed with covid-19 based on a positive polymerase chain reaction (pcr) test result for sars-cov-2 from oropharyngeal swabs, or on a positive detection of covid-19 antigen from nasopharyngeal swabs and typical clinical history; (3) participated in registered clinical trials and received anti-lymphoma treatment within four weeks before covid-19 infection; (4) complete data on clinico-pathological characteristics, treatment approaches and follow-up were available. exclusion criteria: * patients who could not provide detailed information about covid-19 infection.
risk factors for aortic dissection in the chinese patients

Conditions: Persistent Blood Flow in False Lumen of Aortic Dissection

Summary: to evaluate epidemiological features of risk factors for aortic dissection (ad) in chinese patients.

aortic dissection (ad) is a life-threatening cardiovascular disease with high mortality. without optimal treatment, approximately 50% of patients die within one week of the onset of symptoms, and 80% die within 2 weeks. with the change of life-style and the development of diagnostic technology, the incidence and detection rate of ad were increasing in china recently. however, the cause remains unclear. studies showed that ad were associated with some risk factors, such as hypertension, connective tissue disease, iatrogenic injury, drug, pregnancy, etc. it is reported that two thirds patients with ad had a history of hypertension; 50% patients aged \<40 years were accompanied with hereditary marfan syndrome; 13～19% had a familial history of aortic aneurysm or dissection. these epidemiological data were obtained from caucasian population, however, such information was not available for the chinese population. moreover, epidemiological investigation was absent in china, and the assessment of risk factors for ad was mainly referred to the studies from developed countries. therefore, the aim of our study was to evaluate epidemiological features of risk factors for ad in chinese patients using 3045 individuals from the 15 major centers in china. we anticipated that this analysis would provide helpful information preventing and controlling ad in china.

Eligibility criteria:
inclusion criteria: * aortic dissection * acute stage exclusion criteria: -simple aortic aneurysm and pseudoaneurysm were excluded.
iloprost therapy in patients with critical limb ischemia

Conditions: Peripheral Arterial Disease

Summary: monitoring efficacy and safety aspects of iv. iloprost therapy of patients with critical limb ischemia by recording clinical parameters.


Eligibility criteria:
inclusion criteria: * patients who fulfill the internationally defined criteria of critical limb ischemia; * patients who are not eligible for vascular surgery or angioplasty interventions and * patients who are treated with iloprost infusion. * the treating physician has decided iloprost treatment before study enrollment. exclusion criteria: * exclusion criteria are in accordance with the summary of product characteristics of ilomedin.

Keywords: critical limb ischaemia iloprost quality of life visual analogue scale
gluten intolerance in patients with diarrhea predominant irritable bowel syndrome

Conditions: Diarrhea; Diarrhea Predominant Irritable Bowel Syndrome

Summary: the specific hypotheses are: gluten supplementation for four weeks increases small intestinal permeability and accelerates colonic transit in patients with irritable bowel syndrome with diarrhea (ibs-d) or functional diarrhea (fd) who are hla-dq2 positive.

the study design is a double-blind, randomized, controlled, parallel-group, 6-week study comparing the effects of gluten rich versus gluten free diets in diarrhea or diarrhea predominant ibs patients. all participants will keep a daily bowel pattern diary throughout the study. all participants will have negative serum tissue transglutaminase (ttg) assay, and anti-endomysial antibody test, if ttg is positive or equivocal. all participants will have the following studies performed both before and after the 4-week dietary intervention: 1. stool samples to check markers of inflammation such as fecal calprotectin. 2. blood samples to check markers of inflammation and for genetic testing. 3. after ingestion of the mannitol, lactulose and sucralose sugars, urine samples to indirectly measure small intestinal and colonic permeability. 4. after sedation, upper gastrointestinal endoscopy and flexible sigmoidoscopy to obtain 6 mucosal biopsies from the small bowel and sigmoid colon for immunohistochemical analysis. 5. scintigraphy to measure gastrointestinal transit.

Eligibility criteria:
inclusion criteria: 1. diarrhea or diarrhea predominant ibs patients 2. age 18 to 65 3. bdq confirms presence of ibs-d or functional diarrhea, positive by rome iii criteria 4. no restrictions on hospital anxiety depression score 5. no abdominal surgery (except appendectomy and cholecystectomy) exclusion criteria: 1. serum tissue transglutaminase iga or igg positive or medical record of small bowel biopsy suggestive of celiac disease 2. use of tobacco products within the past 6 months (since nicotine may affect intestinal permeability) 3. use of nsaids or aspirin within the past week (since nsaids affect intestinal permeability) 4. use of oral corticosteroids within the previous 6 weeks 5. ingestion of artificial sweeteners such as splendatm (sucralose), nutrasweet tm(aspartame), lactulose or mannitol 2 days before the study begins, e.g., foods to be avoided are sugarless gums or mints and diet soda 6. ingestion of any prescription, over the counter, or herbal medications which can affect gastrointestinal transit 7 days before study begins. 7. any females who are pregnant or trying to become pregnant (due to radiation exposure) 8. bleeding disorders or medications that increase risk of bleeding from mucosal

Keywords: gluten diarrhea or diarrhea predominant irritable bowel syndrome colonic permeability small bowel permeability colonic inflammatory response small bowel inflammatory response
a study of gfh018 in patients with advanced solid tumors

Conditions: Advanced Solid Tumor

Summary: this is the first- in human study of gfh018 comprised of a dose escalation part and a dose expansion part in subjects with advanced solid tumors after single/multiple administration. the study is designed to explore the safety/tolerability, pharmacokinetics, and mtd of gfh018 and to define a rp2d of gfh018.


Eligibility criteria:
inclusion criteria: * eligible subjects must meet all the inclusion criteria listed below: 1. voluntarily participate in this clinical trial and are willing to sign informed consent forms. 2. male or female aged from 18-75 years old (inclusive). 3. diagnosed with histologically or cytologically confirmed advanced solid tumors. 4. evaluable lesions defined by recist v1.1. 5. eastern cooperative oncology group performance status of 0 to 1. 6. subjects or their legal representatives are able to communicate well with investigators and are willing to comply with the protocol and complete the study. exclusion criteria: * eligible subjects should not meet any of the exclusion criteria listed below: 1. with clinically significant cardiac diseases. 2. with clinically significant digestive disorders. 3. other severe disease. 4. pregnant or lactating women. 5. other unfavorable situations for subjects to participate in the study judged by investigators.
chemotherapy monitoring with breast computed tomography (ct)

Conditions: Breast Cancer

Summary: the purpose of this study is to determine if dedicated breast computed tomography can be used successfully to monitor tumor response in breast cancer patients undergoing neoadjuvant chemotherapy.

before undergoing surgery to remove the tumor, it is common for breast cancer patients to first undergo chemotherapy or hormonal therapy. the main goal of the therapy is to reduce the size of the tumor before it is removed. unfortunately, therapy response varies a lot between patients. the development of an effective therapy response monitoring method could reduce the time that a patient undergoes ineffectual therapy or unnecessary therapy after complete response. dedicated breast computed tomography (or breast ct), a new way of imaging the breast, has been introduced in the last few years. breast ct is an x-ray exam that uses 3d imaging to show the breast in its real three dimensional shape. combined with the use of special chemicals called iodine contrast enhancement, breast ct can provide images of both the anatomy and the blood flow in the breast. we propose to use breast ct to carefully monitor the response to therapy of breast cancer patients undergoing therapy before surgery.

Eligibility criteria:
3.1 eligibility criteria * all subjects will be women at least 18 years of age that will undergo standard or research pre-operative hormonal therapy for breast cancer before lumpectomy or mastectomy. * women who have undergone pre treatment breast mr imaging to verify that no additional findings are present. 3.2 ineligibility criteria * subject does not meet any of the inclusion criteria * women with suspected or confirmed pregnancy * women who have had bilateral mastectomy * women who are unable to remain in a prone position on the bct system for the required amount of time * women who cannot give informed consent * women with metastasis * male subjects * women with implants * women with breast augmentation, except for unilateral augmentation done for prior mastectomy * women who are allergic to iodine * women with physical limitations such as, but not limited to: frozen shoulder, recent heart surgery, pace maker, neck problems or any other condition that would prohibit them from lying face down * women who have had problems or reactions to contrast, such as nausea/vomiting, itching, hives, b/p changes, respirator distress, cardiac arrest. * women with history of diabetes, kidney disease, kidney surgery, dialysis, heart disease-such as congestive heart failure, multiple myeloma, sickle cell anemia, lupus, rheumatoid arthritis or other autoimmune disease, recent surgery, chemotherapy, dehydration, high use of nsaids such as ibuprofen

Keywords: neoadjuvant treatment therapy response breast computed tomography
a phase 2 study of e6005 in patients with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the purpose of this study is to evaluate the efficacy and safety profiles of e6005 ointment in patients with atopic dermatitis compared to vehicle. the pharmacokinetic profile after topical application of e6005 is also assessed.


Eligibility criteria:
inclusion criteria * adults of both genders aged 20 to 64 years at the time when the written informed consent is obtained. * outpatients diagnosed with atopic dermatitis. exclusion criteria * patients with a present illness of kaposi's varicelliform eruption, scabies, molluscum contagiosum, impetigo contagious, psoriasis, connective tissue disorder, collagen disorder or netherton's syndrome, etc., which could have an effect on the pathological evaluation of the atopic dermatitis. * patients with active infection that requires oral or intravenous administration of antibiotics, antifungal or antivirus agent/s at baseline. * patients with advanced disease or abnormal laboratory tests that would possibly affect the safety of the subject or the implementation of this study.

Keywords: dermatitis atopic